Molecular Biology and Biochemistry of The
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Product Sheet Info
Product Information Sheet for NR-32875 Yersinia pestis LcrV Protein, Recombinant Biosafety Level: 1 from Escherichia coli Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Catalog No. NR-32875 Public Health Service, Centers for Disease Control and This reagent is the property of the U.S. Government. Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see For research use only. Not for human use. www.cdc.gov/biosafety/publications/bmbl5/index.htm. Contributor and Manufacturer: Disclaimers: BEI Resources You are authorized to use this product for research use only. It is not intended for human use. Product Description: Yersinia pestis (Y. pestis), the causative agent of the plague, Use of this product is subject to the terms and conditions of secretes massive amounts of LcrV (low-calcium-response V the BEI Resources Material Transfer Agreement (MTA). The or V antigen) during infection. Mutations that abrogate the MTA is available on our Web site at www.beiresources.org. expression of LcrV render Y. pestis avirulent.1 LcrV is a While BEI Resources uses reasonable efforts to include multifunctional protein that is central to the activity of the type accurate and up-to-date information on this product sheet, III secretion apparatus of Y. pestis. It has no known catalytic neither ATCC® nor the U.S. Government makes any function, and its biological activity is dependent on interactions warranties or representations as to its accuracy. -
Cellular and Molecular Signatures in the Disease Tissue of Early
Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of -
Application of Hidden Markov Model Based Methods for Gaining Insights Into Protein Domain Evolution and Function
University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Doctoral Dissertations Graduate School 12-2015 Application of Hidden Markov Model based methods for gaining insights into protein domain evolution and function Amit Anil Upadhyay University of Tennessee - Knoxville, [email protected] Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss Part of the Bioinformatics Commons, Computational Biology Commons, and the Genomics Commons Recommended Citation Upadhyay, Amit Anil, "Application of Hidden Markov Model based methods for gaining insights into protein domain evolution and function. " PhD diss., University of Tennessee, 2015. https://trace.tennessee.edu/utk_graddiss/3557 This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. To the Graduate Council: I am submitting herewith a dissertation written by Amit Anil Upadhyay entitled "Application of Hidden Markov Model based methods for gaining insights into protein domain evolution and function." I have examined the final electronic copy of this dissertation for form and content and recommend that it be accepted in partial fulfillment of the equirr ements for the degree of Doctor of Philosophy, with a major in Life Sciences. Igor B. Jouline, Major Professor We have -
Product Sheet Info
Product Information Sheet for NR-796 Monoclonal Anti-Yersinia pestis Low Citation: Calcium Response V-Antigen (LcrV), Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Clone 2C6.2E4.1H8 (produced in vitro) Monoclonal Anti-Yersinia pestis Low Calcium Response V- Antigen (LcrV), Clone 2C6.2E4.1H8 (produced in vitro), NR- Catalog No. NR-796 796.” For research use only. Not for human use. Biosafety Level: 1 Appropriate safety procedures should always be used with Contributor: this material. Laboratory safety is discussed in the following Susan C. Straley, Ph.D., Department of Microbiology, publication: U.S. Department of Health and Human Services, Immunology, and Molecular Genetics, University of Public Health Service, Centers for Disease Control and Kentucky, Lexington, Kentucky, USA Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Manufacturer: Washington, DC: U.S. Government Printing Office, 2009; see BEI Resources www.cdc.gov/biosafety/publications/bmbl5/index.htm. Product Description: Disclaimers: Antibody Class: IgG1ĸ You are authorized to use this product for research use only. Monoclonal antibody prepared against the Yersinia pestis (Y. It is not intended for human use. pestis) low calcium response V-antigen (LcrV) was purified Use of this product is subject to the terms and conditions of from clone 2C6.2E4.1H8 hybridoma supernatant by protein G the BEI Resources Material Transfer Agreement (MTA). The affinity chromatography. The B cell hybridoma was MTA is available on our Web site at www.beiresources.org. generated by the fusion of NS-1 myeloma cells with immunized mouse splenocytes. -
Tianhua Feng
A Comprehensive Dynamical Model for Human CaV1.2 Ion Channel: Structural and Functional Studies by Tianhua Feng A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Pharmaceutical Sciences Faculty of Pharmacy and Pharmaceutical Sciences University of Alberta © Tianhua Feng, 2019 Tianhua Feng M.Sc. Thesis SEP 2019 ABSTRACT Human CaV1.2 is a voltage-gated calcium channel (VGCC), which plays an essential role to maintain a normal cardiac function. Any abnormalities in CaV1.2 can lead to serious cardiac diseases (e.g. cardiac arrhythmias and Timothy syndrome). Thus, understanding the structure- function-dynamics relationships of CaV1.2 is important to avoid and develop treatments of these diseases. Several small molecules (e.g. dihydropyridines and phenylalkylamine) have been identified and designed to modulate the activity of CaV1.2. Yet, their mode and site of action within the CaV1.2 channel are still unclear. In order to understand how these drugs interact with CaV1.2, a detailed three-dimensional structure of the human CaV1.2 channel is necessary. However, such structures have not been resolved yet. Toward this goal, this thesis employed computational molecular modeling techniques to model the transmembrane 1-subunit three-dimensional (3D) structure of the open and closed CaV1.2 channel. We used a combination of homology modeling and threading approaches along with classical and advanced molecular dynamics simulations to explore the conformational transitions between the closed and the open states of the channel. The ultimate goal was to predict the binding orientation and critical interactions for known CaV1.2 modulators. -
Antigen Immune Responses to Lcrv, A
An Age-Old Paradigm Challenged: Old Baboons Generate Vigorous Humoral Immune Responses to LcrV, A Plague Antigen This information is current as of September 27, 2021. Sue Stacy, Amanda Pasquali, Valerie L. Sexton, Angelene M. Cantwell, Ellen Kraig and Peter H. Dube J Immunol 2008; 181:109-115; ; doi: 10.4049/jimmunol.181.1.109 http://www.jimmunol.org/content/181/1/109 Downloaded from References This article cites 44 articles, 6 of which you can access for free at: http://www.jimmunol.org/content/181/1/109.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology An Age-Old Paradigm Challenged: Old Baboons Generate Vigorous Humoral Immune Responses to LcrV, A Plague Antigen1 Sue Stacy,*‡ Amanda Pasquali,* Valerie L. Sexton,† Angelene M. Cantwell,† Ellen Kraig,2*‡ and Peter H. -
Supplementary Table 1A. Genes Significantly Altered in A4573 ESFT
Supplementary Table 1A. Genes significantly altered in A4573 ESFT cells following BMI-1knockdown genesymbol genedescription siControl siBMI1 FC Direction P-value AASS aminoadipate-semialdehyde synthase | tetra-peptide repeat homeobox-like6.68 7.24 1.5 Up 0.007 ABCA2 ATP-binding cassette, sub-family A (ABC1), member 2 | neural5.44 proliferation,6.3 differentiation1.8 and Upcontrol, 1 0.006 ABHD4 abhydrolase domain containing 4 7.51 6.69 1.8 Down 0.002 ACACA acetyl-Coenzyme A carboxylase alpha | peroxiredoxin 5 | similar6.2 to High mobility7.26 group2.1 protein UpB1 (High mobility0.009 group protein 1) (HMG-1) (Amphoterin) (Heparin-binding protein p30) | Coenzyme A synthase ACAD9 acyl-Coenzyme A dehydrogenase family, member 9 9.25 8.59 1.6 Down 0.008 ACBD3 acyl-Coenzyme A binding domain containing 3 7.89 8.53 1.6 Up 0.008 ACCN2 amiloride-sensitive cation channel 2, neuronal 5.47 6.28 1.8 Up 0.005 ACIN1 apoptotic chromatin condensation inducer 1 7.15 7.79 1.6 Up 0.008 ACPL2 acid phosphatase-like 2 6.04 7.6 2.9 Up 0.000 ACSL4 acyl-CoA synthetase long-chain family member 4 6.72 5.8 1.9 Down 0.001 ACTA2 actin, alpha 2, smooth muscle, aorta 9.18 8.44 1.7 Down 0.003 ACYP1 acylphosphatase 1, erythrocyte (common) type 7.09 7.66 1.5 Up 0.009 ADA adenosine deaminase 6.34 7.1 1.7 Up 0.009 ADAL adenosine deaminase-like 7.88 6.89 2.0 Down 0.006 ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 6.57 7.65 2.1 Up 0.000 ADARB1 adenosine deaminase, RNA-specific, B1 (RED1 homolog rat) 6.49 7.13 1.6 Up 0.008 ADCY9 adenylate cyclase 9 6.5 7.18 -
Yersinia Pestis Lcrv Forms a Stable Complex with Lcrg and May Have a Secretion-Related Regulatory Role in the Low-Ca2ϩ Response
JOURNAL OF BACTERIOLOGY, Feb. 1997, p. 1307–1316 Vol. 179, No. 4 0021-9193/97/$04.0010 Copyright q 1997, American Society for Microbiology Yersinia pestis LcrV Forms a Stable Complex with LcrG and May Have a Secretion-Related Regulatory Role in the Low-Ca21 Response MATTHEW L. NILLES, ANDREW W. WILLIAMS, ELZ˙BIETA SKRZYPEK, AND SUSAN C. STRALEY* Department of Microbiology and Immunology, Chandler Medical Center, University of Kentucky, Lexington, Kentucky 40536-0084 Received 15 August 1996/Accepted 6 December 1996 Yersinia pestis contains a virulence plasmid, pCD1, that encodes many virulence-associated traits, such as the Yops (Yersinia outer proteins) and the bifunctional LcrV, which has both regulatory and antihost functions. In addition to LcrV and the Yops, pCD1 encodes a type III secretion system that is responsible for Yop and LcrV secretion. The Yop-LcrV secretion mechanism is believed to regulate transcription of lcrV and yop operons indirectly by controlling the intracellular concentration of a secreted repressor. The activity of the secretion mechanism and consequently the expression of LcrV and Yops are negatively regulated in response to environmental conditions such as Ca21 concentration by LcrE and, additionally, by LcrG, both of which have been proposed to block the secretion mechanism. This block is removed by the absence of Ca21 or by contact with eukaryotic cells, and some Yops are then translocated into the cells. Regulation of LcrV and Yop expression also is positively affected by LcrV. Previously, LcrG was shown to be secreted from bacterial cells when the growth medium lacks added Ca21, although most of the LcrG remains cell associated. -
Yersinia Pestis</Em>: LCRV, F1 Production, Invasion and Oxygen
University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2007-12-20 Surface of Yersinia pestis: LCRV, F1 Production, Invasion and Oxygen: A Dissertation Kimberly Lea Pouliot University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Amino Acids, Peptides, and Proteins Commons, Bacteria Commons, Bacterial Infections and Mycoses Commons, Biological Factors Commons, and the Inorganic Chemicals Commons Repository Citation Pouliot KL. (2007). Surface of Yersinia pestis: LCRV, F1 Production, Invasion and Oxygen: A Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/5ayn-7c77. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/358 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. THE SURFACE OF YERSINIA PESTIS: LCRV, F1 PRODUCTION, INVASION AND OXYGEN A Dissertation Presented Kimberly Lea Pouliot Submitted to the Faculty of the University of Massachusetts Graduate School of Biomedical Sciences, Worcester In partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY December 20 2007 Program of Molecular Genetics and Microbiology December 20 , 2007 THE SURFACE OF YERSINIA PESTIS: LCRV, F1 PRODUCTION, INVASION AND OXYGEN A Dissertation Presented KIMBERLY LEA POULIOT The signatures of the Dissertation Defense Committee signifies completion and a proval as to style and content of the Dissertation Jon D. Goguen , Thesis Advisor Joa n Mecsas, Member of Committee Egil Lien , Member of Committee Madelyn Schmidt, Member of Committee Neal Silverman , Member of Committee The signature of the Chair of the Committee signifies that the written dissertation meets the requirements of the Dissertation Committee John M. -
And Adjuvant-Free Trivalent Plague Vaccine Utilizing Adenovirus-5 Nanoparticle Platform ✉ ✉ Paul B
www.nature.com/npjvaccines ARTICLE OPEN A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform ✉ ✉ Paul B. Kilgore1, Jian Sha1,2 , Jourdan A. Andersson1, Vladimir L. Motin1,2,3,4,5 and Ashok K. Chopra1,2,4,5 A plague vaccine with a fusion cassette of YscF, F1, and LcrV encoding genes in an adenovirus-5 vector (rAd5-YFV) is evaluated for efficacy and immune responses in mice. Two doses of the vaccine provides 100% protection when administered intranasally against challenge with Yersinia pestis CO92 or its isogenic F1 mutant in short- or long- term immunization in pneumonic/bubonic plague models. The corresponding protection rates drop in rAd5-LcrV monovalent vaccinated mice in plague models. The rAd5-YFV vaccine induces superior humoral, mucosal and cell-mediated immunity, with clearance of the pathogen. Immunization of mice with rAd5-YFV followed by CO92 infection dampens proinflammatory cytokines and neutrophil chemoattractant production, while increasing Th1- and Th2-cytokine responses as well as macrophage/monocyte chemo-attractants when compared to the challenge control animals. This is a first study showing complete protection of mice from pneumonic/bubonic plague with a viral vector- based vaccine without the use of needles and the adjuvant. npj Vaccines (2021) 6:21 ; https://doi.org/10.1038/s41541-020-00275-3 1234567890():,; INTRODUCTION There have been reports of naturally occurring F1-negative Y. Yersinia pestis, the causative agent of plague, is a Tier-1 select pestis strains that can be as common as 10–16% in field sampling 18 agent and a re-emerging human pathogen1,2. -
Timing and Targeting of Type III Secretion Translocation of Virulence Effectors in Yersinia
Timing and targeting of Type III secretion translocation of virulence effectors in Yersinia Sofie Ekestubbe Department of Molecular Biology Umeå Centre for Microbial Research (UCMR) Laboratory for Molecular Infection Medicine Sweden (MIMS) Umeå University Umeå 2017 Copyright © Sofie Ekestubbe ISBN: 978-91-7601-639-8 Cover design: Sofie Ekestubbe Elektronisk version tillgänglig på http://umu.diva-portal.org/ Printed by: UmU Print Service, Umeå University Umeå, Sweden 2017 Till min familj Most bacteria are good guys that enable us to live happily ever after. But this is not that kind of story… TABLE OF CONTENTS Table of Contents i Abstract iii Papers Included in this Thesis iv List of Abbreviations v Sammanfattning på Svenska vii 1 Introduction 1 1.1 Virulence 3 1.2 Secretion systems in Gram-negative bacteria 4 1.2.1 Secretion across the bacterial envelope 5 1.2.2 Secretion across host cell membranes 7 1.3 The Type III Secretion System 8 1.3.1 T3SS, a secretion system that translocates 9 1.3.2 Origin and acquisition of the T3SS 9 1.3.3 The structure of the T3SS 11 1.3.3.1 Assembly of the T3SS 12 1.3.4 The function of the T3SS 13 1.3.5 Regulation of the T3SS 13 1.3.5.1 Temperature regulation 14 1.3.5.2 Cell contact 14 1.4 Secretion through the T3S organelle 15 1.4.1 The sorting platform 15 1.5 Translocation by the T3SS 16 1.5.1 The translocator proteins 16 1.5.2 Pore formation 17 1.5.3 The one-step model of translocation 18 1.5.4 The two-step model of translocation 18 1.6 Yersinia 20 1.6.1 The route of infection 20 1.6.2 Phagocytosis 20 -
Polymorphism in the Yersinia Lcrv Antigen Enables Immune Escape
ORIGINAL RESEARCH published: 02 August 2019 doi: 10.3389/fimmu.2019.01830 Polymorphism in the Yersinia LcrV Antigen Enables Immune Escape From the Protection Conferred by an LcrV-Secreting Lactococcus Lactis in a Pseudotuberculosis Mouse Model Catherine Daniel, Amélie Dewitte, Sabine Poiret, Michaël Marceau, Michel Simonet, Laure Marceau, Guillaume Descombes, Denise Boutillier, Nadia Bennaceur, Edited by: Sébastien Bontemps-Gallo, Nadine Lemaître and Florent Sebbane* Fabio Bagnoli, GlaxoSmithKline (Italy), Italy Université de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - Center for Infection and Immunity of Lille, Lille, France Reviewed by: Wayne Robert Thomas, Telethon Kids Institute, Australia Yersinioses caused by Yersinia pestis, Yersinia pseudotuberculosis, and Yersinia Anne Derbise, enterocolitica are significant concerns in human and veterinary health. The link between Institut Pasteur, France Deborah Anderson, virulence and the potent LcrV antigen has prompted the latter’s selection as a major University of Missouri, United States component of anti-Yersinia vaccines. Here, we report that (i) the group of Yersinia species Yinon Levy, Israel Institute for Biological Research encompassing Y. pestis and Y. pseudotuberculosis produces at least five different clades (IIBR), Israel of LcrV and (ii) vaccination of mice with an LcrV-secreting Lactococcus lactis only Vladimir L. Motin, protected against Yersinia strains producing the same LcrV clade as that of used for University of Texas Medical Branch at Galveston, United States vaccination. By vaccinating with engineered LcrVs and challenging mice with strains *Correspondence: producing either type of LcrV or a LcrV mutated for regions of interest, we highlight key Florent Sebbane polymorphic residues responsible for the absence of cross-protection.